The short version of purity testing fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-04. Anything still debated is marked as such rather than presented as settled.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Biopharmaceuticals may be produced from microbial cells (e.g., recombinant E. coli or yeast cultures), mammalian cell lines (see Cell culture) and plant cell cultures (see Plant tissue culture) and moss plants in bioreactors of various configurations, including photo-bioreactors. Important issues of concern are cost of production (low-volume, high-purity products are desirable) and microbial contamination (by bacteria, viruses, mycoplasma). Alternative platforms of production which are being tested include whole plants (plant-made pharmaceuticals).
Oriented strand board is manufactured in wide mats from cross-oriented layers of thin, rectangular wooden strips compressed and bonded together with wax and synthetic resin adhesives. The adhesive resins types used include: urea-formaldehyde (OSB type 1, nonstructural, nonwaterproof); isocyanate-based glue (or PMDI poly-methylene diphenyl diisocyanate–based) in inner regions with melamine-urea-formaldehyde or phenol formaldehyde resin glues at surface (OSB type 2, structural, water resistant on face); phenol formaldehyde resin throughout (OSB types 3 and 4, structural, for use in damp and outside environments). The layers are created by shredding the wood into strips, which are sifted and then oriented on a belt or wire-mesh caul (a heated, ventilated support) and coated with the resin. The layers thus built up are transferred to a forming line and cross-oriented so that strips on the external layers are aligned to the panel's strength axis, while the internal layers are perpendicular. The number of layers placed is determined partly by the thickness of the panel, and is limited by the equipment used. Individual layers can also vary in thickness to give different finished panel thicknesses; typically, a 15 cm (5.9 in) layer will produce a 15 mm (0.59 in) panel thickness. The mat is placed in a thermal press to compress the flakes and bond them by heat activation and curing of the resin. Individual panels are then cut from the mats into finished sizes. Most of the world's OSB is made in the United States and Canada in large production facilities.
Chlorambucil, sold under the brand name Leukeran among others, is a chemotherapy medication used to treat chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, and non-Hodgkin lymphoma. It is given by mouth. Common side effects include bone marrow suppression. Other serious side effects include an increased long term risk of further cancer, infertility, and allergic reactions. Use during pregnancy often results in harm to the baby. Chlorambucil is in the alkylating agent family of medications. It works by blocking the formation of DNA and RNA. Chlorambucil was approved for medical use in the United States in 1957. It is on the World Health Organization's List of Essential Medicines. It was originally made from nitrogen mustard.
=== Media === Castillo has been accused of being evasive with the press. He has not offered any interviews to inform of projects or ideas, and the Council of Ministers has suspended press conferences. Members of Castillo's cabinet have expressed reluctance of communicating with the press, due to the belief that the media maliciously distorts information. According to a poll from 17 August 2021, 78% of respondents believe that the president maintains an inadequate relationship with the press, while only 15% of respondents consider the president's relationship to be adequate. On 20 September 2021, the Free Peru caucus proposed a bill which would declare the "public necessity and national interest the fair and equitable distribution of the electromagnetic and radioelectric spectrum in radio, television and other media." This would allow the government to take direct control of the media given an "exceptional and transitory nature." The bill was signed by 7 members of Free Peru, out of the 37 Congressmen it wields. Some newspapers have claimed that those who gave their signature to the bill are close to Vladimir Cerrón. The opposition has criticized the broad and vague nature of this proposed media bill, which could be applied to the internet and any information platform. Castillo's Foreign Minister, Óscar Maúrtua also condemned the proposed bill, saying that it would "certainly affects international commitments...
Brian David Strahl (born 1970) is an American biochemist and molecular biologist. He is currently a professor in the Department of Biochemistry & Biophysics at the University of North Carolina at Chapel Hill. Strahl is known for his research in the field of chromatin biology and histone modifications. Strahl, with C. David Allis proposed the “histone code hypothesis”.
Sources: en.wikipedia.org
==== United States ==== The US Food and Drug Administration (FDA) considers safe beverages containing less than 0.02% caffeine; but caffeine powder, which is sold as a dietary supplement, is unregulated. It is a regulatory requirement that the label of most prepackaged foods must declare a list of ingredients, including food additives such as caffeine, in descending order of proportion. However, there is no regulatory provision for mandatory quantitative labeling of caffeine, (e.g., milligrams caffeine per stated serving size). There are a number of food ingredients that naturally contain caffeine. These ingredients must appear in food ingredient lists. However, as is the case for "food additive caffeine", there is no requirement to identify the quantitative amount of caffeine in composite foods containing ingredients that are natural sources of caffeine. While coffee or chocolate are broadly recognized as caffeine sources, some ingredients (e.g., guarana, yerba maté) are likely less recognized as caffeine sources. For these natural sources of caffeine, there is no regulatory provision requiring that a food label identify the presence of caffeine nor state the amount of caffeine present in the food. The FDA guidance was updated in 2018.
Since the release of nonbenzodiazepines, also known as z-drugs, in 1992 in response to safety concerns, individuals with insomnia and other sleep disorders have increasingly been prescribed nonbenzodiazepines (2.3% in 1993 to 13.7% of Americans in 2010), and less often prescribed benzodiazepines (23.5% in 1993 to 10.8% in 2010). It is not clear as to whether the new non benzodiazepine hypnotics (Z-drugs) are better than the short-acting benzodiazepines. The efficacy of these two groups of medications is similar. According to the US Agency for Healthcare Research and Quality, indirect comparison indicates that side-effects from benzodiazepines may be about twice as frequent as from nonbenzodiazepines. Some experts suggest using nonbenzodiazepines preferentially as a first-line long-term treatment of insomnia. However, the UK National Institute for Health and Clinical Excellence did not find any convincing evidence in favor of Z-drugs. NICE review pointed out that short-acting Z-drugs were inappropriately compared in clinical trials with long-acting benzodiazepines. There have been no trials comparing short-acting Z-drugs with appropriate doses of short-acting benzodiazepines. Based on this, NICE recommended choosing the hypnotic based on cost and the patient's preference. Older adults should not use benzodiazepines to treat insomnia unless other treatments have failed.
== History == Isavuconazole and isavuconazonium were discovered in Japan by researchers at Roche's research center in Kamakura. Basilea Pharmaceutica, which had been spun out of Roche to develop antimicrobial assets, developed isavuconazonium through Phase II clinical trials. In February 2010, Basilea partnered with Astellas Pharma to complete Phase III trials, obtain regulatory approvals, and market the drug. In 2013 and 2014, the partners won orphan drug designation in the US for isavuconazonium for treating invasive aspergillosis, mucormycosis, and invasive candidiasis. In 2014, Basilea and Astellas amended the agreement to give Astellas sole marketing authority in North America, and Basilea the rights to market in the rest of the world. The US Food and Drug Administration (FDA) granted approval in March 2015, and the European Medicines Agency (EMA) approved it in October 2015. In 2017, Basilea licensed rights to Pfizer to market isavuconazole in Europe and other regions.
It can then be further metabolized to isopropanol which is excreted in breath/urine, or by CYP2E1 into hydroxyacetone (acetol). Acetol can be converted to propylene glycol. This converts to pyruvate (by two alternative enzymes), or propionaldehyde, or to L-lactaldehyde then L-lactate (the common lactate isomer). Another pathway turns acetol to methylglyoxal, then to pyruvate, or to D-lactaldehyde (via S-D-lactoyl-glutathione or otherwise) then D-lactate. D-lactate metabolism (to glucose) is slow or impaired in humans, so most of the D-lactate is excreted in the urine; thus D-lactate derived from acetone can contribute significantly to the metabolic acidosis associated with ketosis or isopropanol intoxication. L-Lactate can complete the net conversion of fatty acids into glucose. The first experiment to show conversion of acetone to glucose was carried out in 1951. This, and further experiments used carbon isotopic labelling. Up to 11% of the glucose can be derived from acetone during starvation in humans. The glycerol released into the blood during the lipolysis of triglycerides in adipose tissue can only be taken up by the liver. Here it is converted into glycerol 3-phosphate by the action of glycerol kinase which hydrolyzes one molecule of ATP per glycerol molecule which is phosphorylated. Glycerol 3-phosphate is then oxidized to dihydroxyacetone phosphate, which is, in turn, converted into glyceraldehyde 3-phosphate by the enzyme triose phosphate isomerase.
=== Background === In the mid-1960s, the United States and Western Europe planned airliners seating twice the then-maximum of some 200 passengers. They were known as airbuses at the time. The Soviet leadership wanted to match them with an aerobus (Russian: аэробус). Alongside the propaganda motive, the USSR genuinely needed an aerobus. Aeroflot expected over 100 million passengers a year within a decade (the 100th million annual passenger was indeed carried on 29 December 1976.) First to respond was OKB-153, the bureau led by Oleg Antonov. It proposed a 724-seat version of the An-22 airlifter. The project was promoted until 1969, ultimately with a 605-passenger interior (383 on the upper deck and 223 on the lower). It did not go ahead due to fears that it would be old-fashioned and because the Kiev-based bureau was close to the deposed Nikita Khrushchev.
Sources: en.wikipedia.org
=== Arabinogalactan sidechains === The structure of the AG glycans consists of a backbone of β-1,3 linked galactose (Gal), with sidechains of β-1,6 linked Gal and have terminal residues of arabinose (Ara), rhamnose (Rha), Gal, fucose (Fuc), and glucuronic acid (GlcA). These AG glycan moieties are assembled by glycosyltransferases (GTs). O-glycosylation of AGPs is initiated by the action of Hyp-O-galactosyltransferases (Hyp-O-GalTs) that add the first Gal onto the protein. The complex glycan structures are then elaborated by a suite of glycosyltransferases, the majority of which are bio-chemically uncharacterized. The GT31 family is one of the families involved in AGP glycan backbone biosynthesis. Numerous members of the GT31 family have been identified with Hyp-O-GALT activity and the core β-(1,3)-galactan backbone is also likely to be synthesized by the GT31 family. Members of the GT14 family are implicated in adding β-(1,6)- and β-(1,3)-galactans to AGPs. In Arabidopsis, terminal sugars such as fucose are proposed to be added by AtFUT4 (a fucosyl transferase) and AtFUT6 in the GT37 family and the terminal GlcA incorporation can be catalysed by the GT14 family. A number of GTs remain to be identified, for example those responsible for terminal Rha.
In 2024, Romania had a GDP (PPP) of around $894 billion and a GDP per capita (PPP) of $47,203. According to the World Bank, Romania is a high-income economy. According to Eurostat, Romania's GDP per capita (PPS) was 77% of the EU average (100%) in 2022, an increase from 44% in 2007 (the year of Romania's accession to the EU), making Romania one of the fastest growing economies in the EU. The Bucharest Stock Exchange (BVB) is the stock exchange of Romania, located in Bucharest. In 2024, the BVB boasted a $74 billion market capitalisation and a trading volume of $7.2 billion. As of 2024, 86 companies were listed on the exchange. In September 2020, FTSE Russell upgraded the BVB from a Frontier market to a Secondary Emerging Market.
== Prognosis == Proper treatment of SAAM often results in full recovery. Recovery can occur even with persistently elevated creatine kinase (CK) levels. Conversely, some people with SAAM do not regain full muscle strength despite the normalization of their CK levels. Longitudinal analysis of a patient cohort revealed that the majority of patients (85%) over 60 years old recovered full strength within four years, compared to less than half of patients below 52 years old, indicating that age during disease onset may be an important prognostic determinant. Once strength recovers, immunosuppressive medications should be tapered. Relapse remains possible during tapering efforts, and some people require long-term immunosuppression. An affected person is more likely to experience permanent muscle damage if they do not receive adequate treatment for a long time. Muscle weakness occurs due to the replacement of some muscle with fatty tissue.
Non-resorbable membranes: The main types of non-resorbable barrier membranes are expanded polytetrafluoroethylene (e-PTFE), high-density polytetrafluoroethylene (d-PTFE), titanium mesh and titanium-reinforced PTFE. Expanded polytetrafluoroethylene (e-PTFE) became the most common non-resorbable membrane used for bone regeneration in the 1990s. Gore-Tex was the most popular type of e-PTFE. The e-PTFE membrane is sintered with pores of 5 - 20 μm within the framework of the material. The e-PTFE membrane behaves as a barrier to prevent fibroblasts and various connective-tissue cells from entering the bone defect in order to allow the slower moving cells that are osteogenic to repopulate the defect. A study used e-PTFE membranes to cover surgically constructed average size bone defects in the mandibular angles of rats. Consequently, the e-PTFE membrane acted as a barrier to soft tissue and sped up bone healing, which took place between 3–6 weeks while no healing occurred in the non-membrane control group during a 22 week period. The biological method of osteopromotion by exclusion is good for predicting ridge growth or defect regeneration. Resorbable membranes: There are many different types of resorbable membranes out there but the main ones are synthetic polymers and natural biomaterials. Synthetic polymers are such that it is a polylactic acid bilayer, or the collagen-derived membranes. These membranes can be obtained from bovine or porcine or dermis. E.g.
=== Use in water treatment === Nelumbo nucifera shows high potential for usage in wastewater treatment removing polluting compounds and heavy metals. It is able to grow in variable water conditions and in low light intensity. Various studies show the successful use of N. nucifera to counteract water eutrophication. The leaves of the floating lotus reduce sunlight reaching the lower part of the water. This suppresses algae growth in N. nucifera aquatic systems and thus, the oxygen content is up to 20% higher than in other aquatic plant systems. Due to intense agricultural practices, nitrogen and phosphorus pollution are major problems in aquatic systems. N. nucifera is able to assimilate a higher content of phosphorus than aquatic plants currently used for water remediation (such as water hyacinth). It also assimilates nitrogen ("denitrification") and creates a habitat for bacterial growth in the water body. Through rhizofiltration, heavy metals – including arsenic, copper, and cadmium – can be removed efficiently from the water. The results observed are impressive showing 96% of copper and 85% cadmium metals removed after a seven-day incubation period. The accumulation of heavy metals doesn't show morphological symptoms of metal toxicity; however, the rhizome quality for human consumption needs further study.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.